ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,709.67
0.34%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Outlook Therapeutics Inc (OTLK)

  7. Outlook Therapeutics Inc (OTLK) News

Outlook Therapeutics (OTLK)

Outlook Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OTLK
DateTimeSourceHeadlineSymbolCompany
28/05/202413:05GlobeNewswire Inc.Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
15/05/202422:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
15/05/202422:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OTLKOutlook Therapeutics Inc
15/05/202422:00GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKOutlook Therapeutics Inc
13/05/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
13/05/202413:50GlobeNewswire Inc.Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
09/05/202413:45GlobeNewswire Inc.Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastNASDAQ:OTLKOutlook Therapeutics Inc
07/05/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OTLKOutlook Therapeutics Inc
06/05/202421:09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OTLKOutlook Therapeutics Inc
02/05/202414:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Retina World Congress 2024NASDAQ:OTLKOutlook Therapeutics Inc
29/04/202414:00GlobeNewswire Inc.Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseNASDAQ:OTLKOutlook Therapeutics Inc
15/04/202421:15GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionNASDAQ:OTLKOutlook Therapeutics Inc
22/03/202411:35GlobeNewswire Inc.Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
18/03/202421:10GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionNASDAQ:OTLKOutlook Therapeutics Inc
12/03/202412:05GlobeNewswire Inc.Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitNASDAQ:OTLKOutlook Therapeutics Inc
11/03/202420:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
08/03/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
08/03/202421:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
08/03/202421:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
08/03/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
07/03/202421:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
14/02/202422:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OTLKOutlook Therapeutics Inc
14/02/202421:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
14/02/202413:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKOutlook Therapeutics Inc
08/02/202412:00Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:OTLKOutlook Therapeutics Inc
08/02/202411:59Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OTLKOutlook Therapeutics Inc
31/01/202421:01Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:OTLKOutlook Therapeutics Inc
31/01/202413:05GlobeNewswire Inc.Outlook Therapeutics® Doses First Subject in NORSE EIGHTNASDAQ:OTLKOutlook Therapeutics Inc
29/01/202422:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:OTLKOutlook Therapeutics Inc
24/01/202422:00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:OTLKOutlook Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:OTLK

Your Recent History

LSE
94VZ
Sg Issuer 24
EU
1962T
1962T
CSE
SKUR.WT
Sekur Private Data
LSE
63UJ
Cred Ag Co 32
EU
I2SBT
SA1 2SBTC INAV
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved